Abnormal DNA methylation, epigenetics, and prostate cancer

William G. Nelson, Srinivasan Yegnasubramanian, Agoston T. Agoston, Patrick J. Bastian, Byron H. Lee, Masashi Nakayama, Angelo M. De Marzo

Research output: Contribution to journalArticle

Abstract

Human prostatic carcinogenesis is characterized by the accumulation of both genetic and epigenetic alterations. The epigenetic changes appear earlier and more consistently, and because the DNA sequence remains intact, may be therapeutically reversible. The mechanism(s) by which epigenetic changes appear during the pathogenesis of prostate cancer have not been established. Nonetheless, new methods for the detection of abnormal DNA methylation, a molecular biomarker of epigenetic alterations, are poised to provide clinical tests potentially useful for prostate cancer detection and diagnosis. In addition, new drugs targeting DNA methyltransferases and other enzymes involved in the maintenance of chromatic structure have been introduced into clinical trials for the treatment of advanced prostate cancers. If sufficiently safe strategies for chromatin modulation can be discovered and developed, epigenetic alterations may become rational targets for both prostate cancer prevention and prostate cancer treatment.

Original languageEnglish (US)
Pages (from-to)4254-4266
Number of pages13
JournalFrontiers in Bioscience
Volume12
Issue number11
DOIs
StatePublished - May 1 2007

Keywords

  • CpG binding domain protein
  • CpG island
  • DNA methylation
  • DNA methyltransferase
  • Epigenetics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'Abnormal DNA methylation, epigenetics, and prostate cancer'. Together they form a unique fingerprint.

  • Cite this